Monster Beverage Corp. MNST
Monster's Coke-like 23x EBITDA multiple masks accounting red flags, eroding US share to Celsius/Alani/BUD, and decaying governance — implying 25%-40% downside to $36-$44.
Thesis
Spruce Point argues that Monster Beverage trades at an irrational premium (6.9x sales, 23x EBITDA) on the assumption international growth and margin expansion can offset US weakness — but their forensic review surfaces stealth PP&E restatements, an unexplained 2023 auditor switch from Deloitte to E&Y at abnormally low fees, capex roughly doubling since 2021 without reconciliation, and Tour Water revenue booked in the Energy segment despite distribution through the CANarchy beer network. Domestic Monster Energy sales went negative quarter-over-quarter in Q3 and Q4 2024 even after a 5% price hike, while Celsius/Alani Nu, GHOST, 1st Phorm/Anheuser-Busch and Molson Coors take shelf space. Co-CEOs Sacks and Schlosberg sold into Monster's own $53 Dutch tender even as the Company repurchased $3.7bn and concentrated CFO/CAO/COO duties under Schlosberg. Re-rated to peer 15x-18x EBITDA, fair value is $36-$44, or 25%-40% downside.
SCQA
Monster Beverage is a $55bn S&P 500 energy-drink leader distributed mainly through Coca-Cola bottlers, founded by Sacks and Schlosberg from microcap Hansen's Natural, now trading at a Coke-equivalent 23x EBITDA premium multiple.
Domestic growth has stalled despite a 5% November 2024 price hike, Celsius/Alani Nu/GHOST and Anheuser-Busch are stealing shelf, and a 2023 auditor change masks stealth PP&E revisions, doubling capex, and segment-bending Tour Water revenue.
Re-rate Monster to peer 15x-18x EBITDA / 4x-5x sales multiples consistent with Celsius-Alani and KDP-GHOST precedent transactions, demand accounting disclosures, separate the concentrated CFO/CAO/COO roles, and weigh insider $53 tender selling against ongoing buybacks.
Re-rating to peer multiples implies a $36-$44 share price (~25%-40% downside from the $57 consensus target) — a poor risk/reward given half of sell-side analysts already lack a Buy and accounting concerns are unpriced.
The three reasons
- 1
US/Canada Monster Energy growth went negative QoQ in H2 2024 even after a 5% price hike, with Celsius/Alani/GHOST/BUD stealing shelf
- 2
Forensic review flags stealth PP&E restatements, doubled capex, low audit fees post Deloitte-to-E&Y switch, and Tour Water booked in Energy segment
- 3
Co-CEOs sold into Monster's own $53 Dutch tender while Company repurchased $3.7bn — implying $36-$44 fair value (25%-40% downside)
Primary demands
- Re-rate Monster to peer 15x-18x EBITDA / 4x-5x sales multiples
- Demand disclosure on stealth PP&E revisions, doubling capex, and Tour Water segment classification
- Question 2023 auditor switch from Deloitte to E&Y at abnormally low fees
- Separate concentrated CFO/CAO/COO duties currently held by Co-CEO Schlosberg
- Disclose purpose of insider stock pledges and Anti-Pledging Policy exemption
KPIs cited
Pattern membership
Precedents cited
- Spruce Point's Xylem (XYL) 2023 short — CEO/CFO departure, -15%
- Spruce Point's Stryker (SYK) 2022 short — operating cash flow strain, -30%
- Spruce Point's Generac (GNRC) 2022 short — distributor lawsuit, -60%
- Spruce Point's Intuit (INTU) 2024 short — guidance cut, -14%
- Spruce Point's Oatly (OTLY) 2021 short — CEO resigned, -91%
- Spruce Point's Boulder Brands 2013 short — CEO resigned
- Spruce Point's WD-40 (WDFC) shorts — Board/CEO retirements, -21%
- Celsius acquiring Alani Nu at 2.8x sales / 12x EBITDA (Feb 2025)
- Keurig Dr Pepper acquiring GHOST Energy at ~3.0x sales (Oct 2024)
Composition what's on the 79 slides
Slide gallery ·
Notes
Classic Spruce Point short — title 'A Monster Short' with custom cover (Spruce Point Energy can / red bear). CIO Ben Axler attributed via cover-quote framing. Multi-pronged thesis: forensic accounting (auditor change, capex/PP&E revisions, segment-bending Tour Water) + competitive (Celsius/Alani/GHOST/BUD shelf erosion) + governance (concentrated officer roles, insider selling into own buyback) + valuation (Coke-multiple unjustified vs M&A comps). Heavy reliance on two former-employee interviews. No SOTP — argues whole-company multiple compression. Stake size not disclosed beyond 'short position'. Closing target $36-$44 (25%-40% downside) from $57.11 reference.